Sfoglia per AUTORE
MASINI C
Collezione ASL Asti

  

Items : 6

Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Sep;155:127-135. doi: 10.1016/j.ejca.2021.06.034. Epub 2021 Aug 6.

2021
ASL Asti
AO Cuneo
ASL Città di Torino
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
ASL Biella

Berruti A; Tucci M; Gennari A; Baier S; Bellissimo AR; Ciccone G; Montagnani F; Comandone A; Chiappino I; Dal Canton O; Masini C; Sacco C; Zamparini M; Sirotova Z; Fea E; Valcamonico F; Vanella P; Ortega C; Buttigliero C; Prati V; Bianchi S; Mosca A; Dalla Volta A; Amoroso D;

Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without (223)Ra. in Cancer biotherapy & radiopharmaceuticals / Cancer Biother Radiopharm. 2021 Jun;36(5):391-396. doi: 10.1089/cbr.2020.4442. Epub 2021 Mar 25.

2021
ASL Asti
AOU San Luigi di Orbassano

Spada M; Salgarello M; Borsatti E; Pignata S; Zichi C; Masini C; Morabito A; Fanti S; Sbrana A; Donner D; Alongi P; Alongi F; Bortolus R; Facchini G; Tucci M; Baldari S; Pinto C; Costa RP; Galli L; Monari F; Caffo O; Frantellizzi V; De Giorgi U; Lo Re G; Cortesi E; De Vincentis G;

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2020 Oct;31(10):1415-1416. doi: 10.1016/j.annonc.2020.06.005. Epub 2020 Jun 18.

2020
ASL Asti
AOU San Luigi di Orbassano

Tucci M; Procopio G; Mucciarini C; Mosca A; Massari F; Masini C; Fratino L; Ermacora P; Fornarini G; Donini M; Ceresoli GL; Buti S; Bortolus R; Berruti A; Baldessari C; Zagonel V; Caffo O; Buttigliero C; Zucali P; Verri E;

Maintenance versus discontinuation of androgen deprivation therapy during docetaxel administration with a continuous or an intermittent schedule in metastatic, castration resistant, prostate cancer patients. A multicenter randomized phase III study of the piemonte oncology network in Tumori

2020
ASL Torino 4
ASL Asti
ASL Biella
ASL Vercelli

Bianchi S; Alessandra M; Prati V; Ortega C; Buttigliero C; Fea E; Vanella P; Valcamonico F; Ciccone G; Sirotova Z; Chiappino I; Dal Canton O; Masini C; Saccot C; Amoroso D; Leone F; Comandone A; Gennari A; Berruti A; Tucci M;

Maintenance versus discontinuation of androgen deprivation therapy during docetaxel administration with a continuous or an intermittent schedule in metastatic, castration resistant, prostate cancer patients: A multicenter randomized phase III study of the Piemonte Oncology Network in Annals of Oncology

2020
ASL Asti
ASL Biella

Berruti A; Mosca A; Bianchi S; Prati V; Ortega C; Buttigliero C; Fea E; Vanella P; Valcamonico F; Ciccone G; Sirotova Z; Chiappino I; Canton OD; Masini C; Sacco† C; Amoroso D; Montagnani F; Comandone A; Gennari A; Tucci M;

Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) sequentially treated with abiraterone acetate (AA) and radium-223 (RA223) in Journal of Clinical Oncology

2020
ASL Asti

Caffo O; Frantellizzi V; Tucci M; Galli L; Monari F; Baldari S; Masini C; Bortolus R; Facchini G; Alongi P; Zichi C; Biasco E; Fanti S; Pignata S; Filice A; Borsatti E; Rossetti S; Spada M; Cortesi E; De Vincentis G;